aspartic acid has been researched along with Rectal Neoplasms in 16 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "alpha-Methylacyl-CoA racemase (AMACR), an enzyme involved in oxidation of branched chain fatty acids and cholesterol metabolites, as well as ibuprofen metabolism, is overexpressed in colorectal adenomas and cancer." | 5.12 | Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. ( Chatterjee, N; Daugherty, SE; Fallin, MD; Hayes, RB; Huang, WY; Isaacs, WB; Platz, EA; Shugart, YY; Welch, R, 2007) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0." | 1.29 | Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (62.50) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daugherty, SE | 1 |
| Platz, EA | 1 |
| Shugart, YY | 1 |
| Fallin, MD | 1 |
| Isaacs, WB | 1 |
| Chatterjee, N | 1 |
| Welch, R | 1 |
| Huang, WY | 1 |
| Hayes, RB | 1 |
| Presant, CA | 1 |
| Ardalan, B | 2 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Bedikian, AY | 1 |
| O'Connell, MJ | 3 |
| Rubin, J | 3 |
| Schutt, AJ | 3 |
| Moertel, CG | 4 |
| Kvols, LK | 2 |
| Hahn, RG | 1 |
| Gertz, MA | 1 |
| Piedbois, P | 1 |
| Lévy, E | 1 |
| Le Bourgeois, JP | 1 |
| Buyse, M | 1 |
| Jodrell, DI | 1 |
| Oster, W | 1 |
| Kerr, DJ | 1 |
| Canney, PA | 1 |
| Yosef, H | 1 |
| Steward, WP | 1 |
| Kaye, SB | 1 |
| Cassidy, J | 1 |
| Finkelstein, SD | 2 |
| Sayegh, R | 2 |
| Bakker, A | 1 |
| Swalsky, P | 1 |
| Christensen, S | 1 |
| Swalsky, PA | 1 |
| Bruckner, HW | 1 |
| Motwani, BT | 1 |
| Buroker, TR | 1 |
| Fleming, TR | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Marschke, RF | 1 |
| Klaassen, DJ | 1 |
| Laurie, JA | 1 |
| Singh, G | 1 |
| Silberman, H | 1 |
| Muggia, FM | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 1 |
| Greenwald, ES | 1 |
| Wernz, JC | 1 |
| Engstrom, PF | 1 |
| Chiuten, DF | 1 |
| Valdivieso, M | 1 |
| Bedikian, A | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Kronberger, L | 1 |
| Fink, E | 1 |
3 reviews available for aspartic acid and Rectal Neoplasms
| Article | Year |
|---|---|
Regional and systemic chemotherapy for advanced colorectal cancer. A review.
Topics: Antineoplastic Agents; Aspartic Acid; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; D | 1983 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Huma | 1991 |
5 trials available for aspartic acid and Rectal Neoplasms
| Article | Year |
|---|---|
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Topics: Adenoma; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid; Case-Control Studies | 2007 |
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials | 1983 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
8 other studies available for aspartic acid and Rectal Neoplasms
| Article | Year |
|---|---|
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasm | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.
Topics: Adenocarcinoma; Aspartic Acid; Biomarkers, Tumor; Codon; Colonic Neoplasms; DNA, Neoplasm; Exons; Fo | 1993 |
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra | 1993 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
[Potassium-magnesium-aspartate therapy in operated cancer patients].
Topics: Adult; Aged; Anemia, Hypochromic; Aspartic Acid; Body Weight; Breast Neoplasms; Female; Hemoglobinom | 1971 |